The Latest Breaking News from Abbott

The British Heart Foundation estimates that more than a million people in the UK are living with heart failure

While Abbott Laboratories has underperformed the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

There's a missing link between college and career.

Will Abbott Elementary score in the awards circuit this year?

Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares?

Broadcom, Abbott, and Nordic American raised dividends, offering strong yields and long-term upside despite market volatility and sector headwinds.

I cannot believe this really happened!

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries.

The sensors provide real-time measurements of sugar levels in the blood, sending that data wirelessly to a device or phone.